Completed Major Depressive Disorder trials in Estonia: Trial Insights

Filters: Condition: Major Depressive Disorder Status: Completed Country / region: Estonia Clear all

29 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2003	2
2004	1
2005	1
2006	2
2007	3
2008	1
2009	2
2010	2
2011	2
2013	1
2014	2
2015	1
2016	3
2017	2
2018	2
2020	2

Trials by status
Category	Trials
Completed	29

Top lead sponsors
Category	Trials
H. Lundbeck A/S	11
Sanofi	4
Pfizer	3
AstraZeneca	2
GlaxoSmithKline	2
AbbVie	1
Forest Laboratories	1
Janssen Research & Development, LLC	1
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	1
Shire	1

Top conditions
Category	Trials
Major Depressive Disorder	29
Depressive Disorder	2
Dementia	1
Mental Disorders	1
Mood Disorders	1
Psychomotor Disorders	1

Trials

Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression NCT04448431Phase 4CompletedH. Lundbeck A/SStarted 2020
Vortioxetine in Patients With Depression and Early Dementia NCT04294654Phase 4CompletedH. Lundbeck A/SStarted 2020
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression NCT03766867Phase 2CompletedH. Lundbeck A/SStarted 2018
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone NCT03738215Phase 3CompletedAbbVieStarted 2018
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide NCT03039192Phase 3CompletedJanssen Research & Development, LLCStarted 2017
Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age NCT03108625Phase 3CompletedH. Lundbeck A/SStarted 2017
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder NCT02919501Phase 2CompletedH. Lundbeck A/SStarted 2016
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) NCT02709746Phase 3CompletedH. Lundbeck A/SStarted 2016
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) NCT02709655Phase 3CompletedH. Lundbeck A/SStarted 2016
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment NCT02400346Phase 3CompletedH. Lundbeck A/SStarted 2015
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder NCT02279953Phase 3CompletedH. Lundbeck A/SStarted 2014
Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder NCT02279966Phase 3CompletedH. Lundbeck A/SStarted 2014
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment NCT01838681Phase 3CompletedH. Lundbeck A/SStarted 2013
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder NCT01469377Phase 2CompletedForest LaboratoriesStarted 2011
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder NCT01436162Phase 3CompletedShireStarted 2011
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder NCT01180400Phase 3CompletedAstraZenecaStarted 2010
A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder NCT01034995Phase 2CompletedSanofiStarted 2010
Clinical Study to Test a New Drug to Treat Major Depression NCT00976560Phase 2CompletedGlaxoSmithKlineStarted 2009
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder NCT00887224Phase 3CompletedPfizerStarted 2009
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder NCT00629551Phase 3CompletedSanofiStarted 2008
A Study Of New Medicine (GSK 372475) For The Treatment Of Depression NCT00448058Phase 2CompletedGlaxoSmithKlineStarted 2007
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder NCT00432614Phase 3CompletedSanofiStarted 2007
Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment NCT03927950Phase 4CompletedUniversity of TartuStarted 2007
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder NCT00388973Phase 3CompletedAstraZenecaStarted 2006
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder NCT00300378Phase 3CompletedWyeth is now a wholly owned subsidiary of PfizerStarted 2006

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory